About Us

Mark Iwicki

Chairman and Chief Executive Officer

Mr. Iwicki has more than 25 years of experience leading all aspects of R&D and commercialization in the biopharmaceutical industry. He is the Chairman, President and CEO of Kala Pharmaceuticals and was previously the CEO of Civitas Therapeutics which was acquired by Acorda Therapeutics.  Read More »


Howard B. Rosen

Board Member

Mr. Rosen has served as a member of our board of directors since January 2014. Since 2008, Mr. Rosen has served as a consultant to several companies in the biotechnology industry. He has also served as a lecturer at Stanford University in Chemical Engineering since 2009 and in Management since 2011.  Read More »


Gregory Grunberg, MD, MBA

Board Member
Managing Director, Longitude Capital

Dr. Grunberg has served as a member of our board of directors since April 2016. Dr. Grunberg has been a Managing Director at Longitude Capital Management Co., LLC, a venture capital firm and a current 5% stockholder, or Longitude, since 2012 and has focused on drug development and medical technology solutions.  Read More »


Rajeev Shah

Board Member
Managing Director & Portfolio Manager, RA Capital

Mr. Shah has served as a member of our board of directors since July 2015. Since 2004, Mr. Shah has been a managing partner at RA Capital Management, L.P., a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics and current 5% beneficial stockholder.   Read More »


Robert Paull

Board Member
Co-Founder and Venture Partner, Lux Capital

Mr. Paull has served as a member of our board of directors since July 2009. Mr. Paull was a co-founder of, and since 2014 has been a Venture Partner at, Lux Capital Management, or Lux Capital, where he focuses on healthcare ventures.   Read More »


Andrew I. Koven

Board Member

Mr. Koven has served as a member of our board of directors since September 2017 and as our Lead Independent Director since December 2018. Mr. Koven was, until his retirement in January 2019, the President and Chief Business Officer of Aralez Pharmaceuticals Inc., or Aralez, a public specialty pharmaceutical company, and served in that role with the company’s predecessor, Pozen Inc., commencing in June 2015.  Read More »


Gregory Perry

Board Member

Mr. Perry has served as a member of our board of directors since February 2018. Mr. Perry has served as Chief Financial Officer for Finch Therapeutics Group, Inc., a private therapeutics company focused on the microbiome, since June 2018. Previously, he served as Chief Financial and Administrative Officer of Novelion Therapeutics Inc., or Novelion, a public biopharmaceutical company, from November 2016 to December 2017.  Read More »